{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:42Z","timestamp":1791849402290,"version":"4.3.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"DOI":"10.1007\/s13300-026-01924-x","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:28:01Z","timestamp":1791826081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Off-label Use of U-500 Regular Insulin with a Tubeless Automated Insulin Delivery System in Type 1 Diabetes and Severe Insulin Resistance: A Case Report"],"prefix":"10.1007","author":[{"given":"Bleuenn","family":"Dreves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-7355","authenticated-orcid":false,"given":"Michael","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"Suppl 1","key":"1924_CR1","first-page":"A334","volume":"56","author":"M Khan","year":"2007","unstructured":"Khan M, Lee YY. The pharmacokinetic and pharmacodynamic properties of regular U-500 insulin in healthy non-obese subjects. Diabetes. 2007;56(Suppl 1):A334\u20135.","journal-title":"Diabetes."},{"key":"1924_CR2","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.2337\/dc11-0721","volume":"34","author":"A de la Pe\u00f1a","year":"2011","unstructured":"de la Pe\u00f1a A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34:2496\u2013501.","journal-title":"Diabetes Care"},{"key":"1924_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.4158\/EP10014.OR","volume":"16","author":"WS Lane","year":"2010","unstructured":"Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB. A prospective trial of U-500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract. 2010;16:778\u201384.","journal-title":"Endocr Pract."},{"key":"1924_CR4","first-page":"1","volume":"17","author":"A Boldo","year":"2011","unstructured":"Boldo A, Comi RJ. Clinical experience with U-500 insulin: risks and benefits. Endocr Pract. 2011;17:1\u201317.","journal-title":"Endocr Pract"},{"key":"1924_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1177\/193229681100500429","volume":"5","author":"S Reutrakul","year":"2011","unstructured":"Reutrakul S, Brown RL, Koh CK, Hor TK, Baldwin D. Use of U-500 regular insulin via continuous subcutaneous insulin infusion: clinical practice experience. J Diabetes Sci Technol. 2011;5:1025\u20136.","journal-title":"J Diabetes Sci Technol"},{"key":"1924_CR6","volume":"12","author":"M Vasigh","year":"2020","unstructured":"Vasigh M, Mohammady J, Hopkins R. Insulin edema with use of U-500 regular insulin in a hybrid closed-loop insulin pump. Cureus. 2020;12:e10886.","journal-title":"Cureus"},{"key":"1924_CR7","doi-asserted-by":"crossref","unstructured":"Aurora J Jr, Saraswat A. Concentrated regular U-500 insulin in an automated insulin delivery system: a case report. J Endocr Soc. 2023;7(Suppl 1):bvad114.873.","DOI":"10.1210\/jendso\/bvad114.873"},{"key":"1924_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/15209156251359167","author":"PY Chu","year":"2025","unstructured":"Chu PY, Parimi N, Wolf RM, Brown EA, Kelly A, Marks BE. Real-world safety and effectiveness of U-200 insulin use in automated insulin delivery systems in adolescents and young adults with type 1 diabetes. Diabetes Technol Ther. 2025. https:\/\/doi.org\/10.1177\/15209156251359167.","journal-title":"Diabetes Technol Ther"},{"key":"1924_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112047","volume":"222","author":"LC Mendoza","year":"2025","unstructured":"Mendoza LC, Cohen O, Smaniotto V, Corcoy R. Switching to insulin lispro U-200 in a pregnant woman using a 780G advanced hybrid closed-loop system led to a rapid improvement in glucose metrics. Diabetes Res Clin Pract. 2025;222:112047.","journal-title":"Diabetes Res Clin Pract."},{"key":"1924_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2337\/cd24-0110","volume":"43","author":"T Akcan","year":"2025","unstructured":"Akcan T, Needleman L, Basina M. Safe and effective use of U-200 insulin with automated insulin delivery systems. Clin Diabetes. 2025;43:449\u201352.","journal-title":"Clin Diabetes"},{"key":"1924_CR11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/dom.12286","volume":"16","author":"W Lane","year":"2014","unstructured":"Lane W, Weinrib S, Rappaport J, Hale C. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes Obes Metab. 2014;16:827\u201332.","journal-title":"Diabetes Obes Metab"},{"key":"1924_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041303","volume":"14","author":"M Infante","year":"2025","unstructured":"Infante M, Silvestri F, Padilla N, et al. Unveiling the therapeutic potential of the second-generation incretin analogs semaglutide and tirzepatide in type 1 diabetes and latent autoimmune diabetes in adults. J Clin Med. 2025;14:1303.","journal-title":"J Clin Med"},{"key":"1924_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2337\/dc22-1054","volume":"46","author":"E Svehlikova","year":"2023","unstructured":"Svehlikova E, et al. Pharmacokinetics and pharmacodynamics of a novel U500 insulin aspart formulation: a randomized, double-blind, crossover study in people with type 1 diabetes. Diabetes Care. 2023;46:757\u201364.","journal-title":"Diabetes Care"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01924-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01924-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01924-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:34:15Z","timestamp":1791848055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01924-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":13,"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01924-x","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bleuenn Dreves declares consultant and\/or speaker fees and\/or research support from Ascendis Pharma, Gilead, Lilly, Sanofi, Abbott, Novo Nordisk, and Boehringer Ingelheim. Michael Joubert declares consultant and\/or speaker fees and\/or research support from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Dexcom, Glooko, Insulet, ISIS Diab\u00e8te, LifeScan, Lilly, Medtronic, Novo Nordisk, Qualees, Roche Diabetes, Sanofi, Tandem, and Ypsomed. Michael Joubert is an Editorial Board member of Diabetes Therapy. Michael Joubert was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Under French regulations, this single-patient case report, based exclusively on routine clinical care, did not constitute research involving human participants and therefore did not require approval by an ethics committee. The patient provided written informed consent for publication of the case and accompanying images. A copy of the written consent is available for review by the Editor on reasonable request.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}